Skip to main content
Premium Trial:

Request an Annual Quote

Arkansas BCBS Covering Signal Genetics' Multiple Myeloma Assay

NEW YORK (GenomeWeb News) – Signal Genetics today said that Arkansas Blue Cross Blue Shield will cover the company's molecular assay for multiple myeloma.

Arkansas BCBS has issued a positive coverage decision and in-network provider status for Signal Genetics' MyPRS gene expression profiling assay, which is performed on isolated plasma cells from a patient's bone marrow. By genomically profiling the cells, a personalized prognostic score and molecular subtype can be obtained that may be predictive of outcomes in patients newly diagnosed with the disease or who have relapsed multiple myeloma, the New York-based molecular diagnostics company said.

Signal said that more than 20,000 people are diagnosed with the disease each year in the US.

"With multiple myeloma, achieving prognostic certainty is critical to optimize therapies and ultimately, patient outcome," Signal President and CEO Sam Riccitelli said in a statement. "This announcement is part of our efforts to work with payers across the country to make this important prognostic test available to clinicians and their patients, helping to support personalized medicine with the goal of improving outcomes.”

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.